Stockscreener 앱 받기
3.01
1.63%
-0.05
시간 외 거래:
2.94
-0.07
-2.33%
전일 마감가:
$3.06
열려 있는:
$3.02
하루 거래량:
1.58M
Relative Volume:
1.48
시가총액:
$203.56M
수익:
$488.00K
순이익/손실:
$-41.44M
주가수익비율:
-3.2366
EPS:
-0.93
순현금흐름:
$-31.47M
1주 성능:
-14.97%
1개월 성능:
-29.01%
6개월 성능:
+16.67%
1년 성능:
-43.95%
1일 변동 폭
$2.94
$3.08
1주일 범위
$2.94
$3.57
52주 변동 폭
$2.01
$6.38
Cardiff Oncology Inc Stock (CRDF) Company Profile
명칭
Cardiff Oncology Inc
전화
858-952-7570
주소
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
CRDF을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
3.01 | 203.56M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-06 | 개시 | Craig Hallum | Buy |
| 2022-01-05 | 개시 | William Blair | Outperform |
| 2021-12-08 | 개시 | Robert W. Baird | Outperform |
| 2021-08-09 | 재개 | Maxim Group | Buy |
| 2020-10-22 | 개시 | H.C. Wainwright | Buy |
| 2020-10-08 | 개시 | Piper Sandler | Overweight |
모두보기
Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스
Charles Schwab Investment Management Inc. Sells 19,629 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Is Cardiff Oncology, Inc. (CRDF) The Hot Biotech Stock Under $5? - Insider Monkey
Bank of New York Mellon Corp Increases Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
10 Hot Biotech Stocks Under $5 - Insider Monkey
Is Cardiff Oncology 15% bump due to positive clinical trials or a short squeeze? - Mugglehead
Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Report Preview: Wha - GuruFocus.com
Future Industry Growth Of Metastatic Prostate Cancer Market - openPR
Rhumbline Advisers Buys 10,290 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - Canada NewsWire
Cardiff Oncology’s Earnings Call: Optimism Amid Challenges - MSN
Financial Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Cardiff Oncology (NASDAQ:CRDF) - Defense World
All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy - Nasdaq
Q1 Earnings Forecast for CRDF Issued By William Blair - Defense World
Cardiff Oncology (NASDAQ:CRDF) Price Target Raised to $17.00 - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Cardiff Oncology (NASDAQ:CRDF) Stock - MarketBeat
Cardiff Oncology Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Cardiff Oncology (NASDAQ:CRDF) Announces Quarterly Earnings Results - MarketBeat
Cardiff Oncology plans mixed shelf offering - MSN
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2024 Earnings Call Transcript - Insider Monkey
Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Call Highlights: Financial Fortification and ... - Yahoo Finance
Cardiff Oncology Highlights Progress in Cancer Trials - TipRanks
Cardiff Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: Cardiff Oncology Q4 2024 highlights strategic advances - Investing.com
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - The Manila Times
Cardiff Oncology Reports Positive Initial Efficacy Data for Onvansertib in Metastatic Colorectal Cancer and Secures $40 Million Financing - Nasdaq
Cardiff Oncology, Inc. SEC 10-K Report - TradingView
Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Cardiff Oncology Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Cardiff Oncology (CRDF) Projected to Post Earnings on Thursday - MarketBeat
Cardiff Oncology to Present at Upcoming Investor Conferences - The Manila Times
Can Cardiff Oncology's New Colorectal Cancer Approach Transform Treatment? CEO to Reveal Strategy - StockTitan
Critical Contrast: Cardiff Oncology (NASDAQ:CRDF) versus Vir Biotechnology (NASDAQ:VIR) - Defense World
Cardiff Oncology (CRDF) to Release Earnings on Thursday - Defense World
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update - The Manila Times
Can Cardiff Oncology's Q4 Earnings Reveal New Cancer Drug Progress? - StockTitan
Bullish Cardiff Oncology Insiders Rewarded As Their Investment Rises To US$1.81m - Yahoo Finance
Cardiff Oncology, Inc. (NASDAQ:CRDF) Sees Significant Growth in Short Interest - MarketBeat
Taking on analysts’ expectations and winning: Cardiff Oncology Inc (CRDF) - SETE News
Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib (NASDAQ:CRDF) - Seeking Alpha
Cardiff Oncology, Inc. (NASDAQ:CRDF) Sees Significant Increase in Short Interest - Defense World
SG Americas Securities LLC Sells 6,103 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Compass Therapeutics (NASDAQ:CMPX) & Cardiff Oncology (NASDAQ:CRDF) Critical Review - Defense World
Cardiff Oncology Inc (CRDF) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Cardiff Oncology Inc (CRDF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):